anti-gp41 (HIV) mAb (rec.) (A2)

AdipoGen Life Sciences
Product Code: AG-27B-6323
Product Group: Primary Antibodies
CodeSizePrice
AG-27B-6323-C05050 ug£298.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Antibody Isotype: Human IgG1
Antibody Clonality: Recombinant Antibody
Antibody Clone: A2
Regulatory Status: RUO
Target Species: Virus
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Fluorescence-activated cell sorting (FACS)
  • Immunoprecipitation (IP)
Shipping:
BLUE ICE
Storage:
Short Term: +4°C Long Term: -20°C

Further Information

Alternate Names/Synonyms:
Glycoprotein 41; Envelope Protein gp41, HIV; HIV Transmembrane Protein gp41; HTLV-III gp41
Concentration:
1 mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.
Immunogen:
Lectin-purified gp140 (from ADA.C1 strain).
Long Description:
Recombinant Antibody. Recognizes gp41 from HIV. Targets the pocket-binding domain of gp41 CHR when CHRs maintain in the trimer conformation. Applications: ELISA, FACS, IP. Clone: A2. Isotype: Human IgG1. Formulation: Liquid. In PBS. HIV-1 Env consists of two subunits: the surface-exposed glycoprotein gp120, which contains the receptor (CD4) and coreceptor (CCR5 or CXCR4) binding sites, and the transmembrane subunit gp41, which is critical for virus-cell membrane fusion. Sequential binding of HIV-1 to its receptor and coreceptor are the first steps critical for viral entry, whereby CD4 binding triggers a series of conformational changes in Env involving both gp120 and gp41. In gp120, CD4 binding induces rearrangement of the variable loops V1/V2 and formation of the bridging sheet, which allows for repositioning of the V3 loop to facilitate coreceptor binding. In gp41, CD4 binding triggers exposure of the buried N-terminal HR1 domain and its formation into a trimeric coiled-coil structure. Upon receptor and coreceptor binding, the fusion peptide in gp41 is inserted into the cell membrane and the HR1 and HR2 regions rearrange to form the six-helix bundle, which is critical for creation of the fusion pore to enable membrane fusion and efficient viral entry. The antibody clone A2 was found to specifically target the pocket-binding domain of gp41 CHR when CHRs maintain in the trimer conformation.
Other data:
This is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
Package Type:
Vial
Product Description:
HIV-1 Env consists of two subunits: the surface-exposed glycoprotein gp120, which contains the receptor (CD4) and coreceptor (CCR5 or CXCR4) binding sites, and the transmembrane subunit gp41, which is critical for virus-cell membrane fusion. Sequential binding of HIV-1 to its receptor and coreceptor are the first steps critical for viral entry, whereby CD4 binding triggers a series of conformational changes in Env involving both gp120 and gp41. In gp120, CD4 binding induces rearrangement of the variable loops V1/V2 and formation of the bridging sheet, which allows for repositioning of the V3 loop to facilitate coreceptor binding. In gp41, CD4 binding triggers exposure of the buried N-terminal HR1 domain and its formation into a trimeric coiled-coil structure. Upon receptor and coreceptor binding, the fusion peptide in gp41 is inserted into the cell membrane and the HR1 and HR2 regions rearrange to form the six-helix bundle, which is critical for creation of the fusion pore to enable membrane fusion and efficient viral entry. The antibody clone A2 was found to specifically target the pocket-binding domain of gp41 CHR when CHRs maintain in the trimer conformation.
Purity:
>95% (SDS-PAGE)
Source / Host:
Protein A purified from HEK293 cell culture supernatant.
Specificity:
Recognizes gp41 from HIV. Targets the pocket-binding domain of gp41 CHR when CHRs maintain in the trimer conformation.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.Stable for at least 1 week when stored at +4°C.

References

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody: M. Trott, et al.; PLoS One 9, e97478 (2014)